NCT02776761View on ClinicalTrials.gov

A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

September 27, 2017

Study Completion Date

September 27, 2017

Conditions
Hantaan Virus
Interventions
BIOLOGICAL

Hantaan Vaccine:

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

BIOLOGICAL

Puumala Vaccine

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

BIOLOGICAL

Hantaan/Puumala Vaccine

DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline

Trial Locations (1)

20910

WRAIR Clinical Trials Center, Silver Spring

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT02776761 - A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine | Biotech Hunter | Biotech Hunter